Wells Fargo & Company Phio Pharmaceuticals Corp. Transaction History

Wells Fargo & Company

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$0.33 - $63.51 $0 - $127	2 Added 2.2%	93 $0
Q3 2022 Nov 14, 2022	BUY	$0.62 - $66.43 $19 - $2,125	32 Added 54.24%	91 $0
Q2 2022 Aug 12, 2022	BUY	$0.64 - $2.35 $3 - $14	6 Added 11.32%	59 $0
Q3 2021 Nov 15, 2021	SELL	$1.62 - $2.28 $4 - $6	-3 Reduced 5.36%	53 $0
Q2 2021 Aug 16, 2021	BUY	$1.87 - $2.8 $29 - $44	16 Added 40.0%	56 $0
Q1 2021 May 13, 2021	BUY	$2.48 - $4.05 $17 - $28	7 Added 21.21%	40 $0
Q3 2020 Nov 05, 2020	BUY	$1.95 - $2.94 $29 - $44	15 Added 83.33%	33 $0
Q1 2020 May 14, 2020	BUY	$1.77 - $12.93 $31 - $232	18 New	18 $0

Ticker PHIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 13,658,700
Market Cap $25M
Description
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.